机构:[1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, 999078, Macau[2]Center for medical genetics, Central South University, Changsha 410031, Hunan, China[3]Key Laboratory of Protein Modification and Degradation, State Key Laboratory of Respiratory Disease, College of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, Guangdong, China[4]Mr. & Mrs. Ko Chi-Ming Centre for Parkinson’s Disease Research, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong Special Administrative Region[5]Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[6]Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430072, Hubei, China[7]Department of Biomedical Sciences, Faculty of Health Sciences, Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, 999078, Macau[8]Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway
National Natural Science Foundation of China (No. 82271455), the University of Macau grants (No. MYRG2022-00094-ICMS), the Guangdong Basic and Applied Basic Research Foundation (No. 2022A1515012416), the Science and Technology Development Fund, Macau SAR (No. 0128/2019/A3), and the Shenzhen Fundamental Research Program (No. SGDX20210823103804030). Evandro Fei Fang is supported by Cure Alzheimer’s Fund (#282952), HELSE SØR-ØST (#2020001, #2021021, #2023093), the Research Council of Norway (#262175, #334361), Molecule AG/VITADAO (#282942), NordForsk Foundation (#119986), Akershus University Hospital (#269901, #261973, #262960), the Civitan Norges Forskningsfond for Alzheimers sykdom (#281931), the Czech Republic-Norway KAPPA programme (with Martin Vyhn´alek, #TO01000215), and the Rosa sløyfe/Norwegian Cancer Society & Norwegian Breast Cancer Society (#207819).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|1 区医学
小类|1 区药学
最新[2025]版:
大类|2 区医学
小类|1 区药学
第一作者:
第一作者机构:[1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, 999078, Macau
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Dong Yu,Zhuang Xu-Xu,Wang Yi-Ting,et al.Chemical mitophagy modulators: Drug development strategies and novel regulatory mechanisms[J].Pharmacological research.2023,194:106835.doi:10.1016/j.phrs.2023.106835.
APA:
Dong Yu,Zhuang Xu-Xu,Wang Yi-Ting,Tan Jieqiong,Feng Du...&Lu Jia-Hong.(2023).Chemical mitophagy modulators: Drug development strategies and novel regulatory mechanisms.Pharmacological research,194,
MLA:
Dong Yu,et al."Chemical mitophagy modulators: Drug development strategies and novel regulatory mechanisms".Pharmacological research 194.(2023):106835